Evaluation of Comparative Efficacy and Pleiotrophy of the Available Three SGLT2 Inhibitors in Type 2 DM Subjects
Abstract
INTRODUCTION: Type 2 diabetes mellitus (T2DM) is a chronic disease that is
associated with obesity and the progressive development of hyperglycemia.
Increased body fat is associated with the development of insulin resistance in
muscle and in the liver, particularly if excess fat is deposited in these tissues .
Initially, the pancreas is able to overcome this insulin resistance by producing more
insulin, but in diabetes there is a progressive failure of β-cell output, resulting first
in glucose intolerance and then overt T2DM. In addition to these established
factors, it is now known that multiple defects, involving numerous metabolic
pathways and organ systems, contribute to the progression of hyperglycemia in
T2DM. It include adipocytes (accelerated lipolysis), the gastrointestinal tract
(incretin deficiency/resistance), pancreatic α-cells (hyperglucagonemia), the brain
(insulin resistance), and the kidneys (increased glucose reabsorption).1
Diabetes is a worldwide growing public health problem with high risks
of severe micro vascular and macrovascular complications. Diabetic nephropathy
(DN) is a major burden among the chronic complications of diabetes, given that it
affects the 30% of patients with diabetes. Indeed, DN is the most common cause of
end-stage renal disease . Known risk factors for DN include hyperglycemia,
hypertension, dyslipidemia, smoking, and obesity as well as ethnic, familial, and
genetic predispositions. Thus, large intervention trials on the impact…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.